Hepatic and Extrahepatic Insulin Clearance in Mice with Double Deletion of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Receptors

双敲除胰高血糖素样肽-1和葡萄糖依赖性胰岛素促泌多肽受体的小鼠的肝脏和肝外胰岛素清除率

阅读:1

Abstract

The aim of this study was to investigate whether incretins, at physiological levels, affect hepatic and/or extrahepatic insulin clearance. Hepatic and extrahepatic insulin clearance was studied in 31 double incretin receptor knockout (DIRKO) and 45 wild-type (WT) mice, which underwent an Intravenous Glucose Tolerance Test (IVGTT). A novel methodology based on mathematical modeling was designed to provide two sets of values (FE(L-P1), CL(P-P1); FE(L-P2), CL(P-P2)) accounting for hepatic and extrahepatic clearance in the IVGTT first and second phases, respectively, plus the respective total clearances, CL(T-P1) and CL(T-P2). A statistically significant difference between DIRKO and WT was found in CL(T-P1) (0.61 [0.48-0.82] vs. 0.51 [0.46-0.65] (median [interquartile range]); p = 0.02), which was reflected in the peripheral component, CL(P-P1) (0.18 [0.13-0.27] vs. 0.15 [0.11-0.22]; p = 0.04), but not in the hepatic component, FE(L-P1) (29.7 [26.7-34.9] vs. 28.9 [25.7-32.0]; p = 0.18). No difference was detected between DIRKO and WT in CL(T-P2) (1.38 [1.13-1.75] vs. 1.69 [1.48-1.87]; p = 0.10), neither in CL(P-P2) (0.72 [0.64-0.81] vs. 0.79 [0.69-0.87]; p = 0.27) nor in FE(L-P2) (37.8 [35.1-43.1] vs. 39.8 [35.8-44.2]; p = 0.46). In conclusion, our findings suggest that the higher insulin clearance observed in DIRKO compared with WT during the IVGTT first phase may be due to its extrahepatic component.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。